Autolus Therapeutics maintains its 2026 AUCATZYL revenue guidance amid early U.S. and U.K. launch momentum.
Autolus Therapeutics reaffirmed its 2026 revenue guidance of $120M to $135M for AUCATZYL, citing strong early traction in the U.S. and U.K. markets. The company targets a peak gross margin of 65%-70% for its acute lymphoblastic leukemia therapy.
The guidance aligns with prior projections, reflecting steady progress in commercialization. Q1 2026 performance indicated growing adoption, though specific revenue figures for the quarter were not disclosed.
Management highlighted confidence in the product’s market potential but did not detail immediate market reactions or stock movements.